In addition, it has been reported that SGLT2 inhibitors, that have been recently approved for the treatment of CKD, have a nephroprotective effect by inhibiting mTORC1 by increasing ketone levels in renal tissue [5]. This evidence concerns the gene SLC5A2 and chronic kidney disease.